Table 3.
PUBLISHED STUDIES ON CBM
| Article | Study type | Patient Population | Treatment with CBM | Follow-up, wk | Main Indications | Results | Analgesics | Adverse Events |
|---|---|---|---|---|---|---|---|---|
| Chelliah et al (2018)16 | Case series | 3 | Topical CBD | ND | Epidermolysis bullosa | Significant reduction of blistering and pain | Morphine; naproxene and gabapentin | NR |
| Maida and Corban (2017)17 | Case series | 3 | TCBM | 33; 9; 21 | Pyoderma gangrenosum | Significant pain reduction; significant reduction of opioid requirement | Opioid; acetaminophen | NR |
| Maida (2017)6 | Case report | 1 | Medical cannabis (vaporized topical oil) | 4 | Skin squamous cell cancer | Modest regression of malignant wound; reduction in pain and analgesic requirement | Hydromorphone, pregabalin | NR |
| Maida et al (2021)15 | Reports from prospective open-label serial case series | 1 | TCBM | 14 | Sickle cell disease leg ulcer | Faster wound healing than expected | Hydromorphone | NR |
| Maida et al (2020)18 | Reports from prospective open-label serial case series | 2 | TCBM | 11 | Non-uremic calciphylaxis leg ulcers | Faster wound healing than expected; reduction in analgesic requirement | Codeine and acetaminophen; morphine sulfate | NR |
| Maida et al (2021)19 | Reports from prospective open-label serial case series | 14 (3 lost to follow-up) | TCBM | ND | Venous leg ulcers | Faster wound healing than expected; complete wound closure within a median of 34 d | ND | NR |
Abbreviations: CBM, cannabis-based medicine; ND, not defined; NR, not referred; TCBM, topical cannabis-based medicine (composed of mixtures of cannabinoids, terpenes, and flavonoids).